The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

AstraZeneca and CSPC Pharmaceutical have signed a research deal worth up to USD 5.3 billion to co-develop oral therapies for chronic and immunological diseases. CSPC will lead discovery in China using ...

Quantum computing stocks are high-risk, high-reward plays, where the tech still feels futuristic, but the potential upside could be transformative for your portfolio. While giants like NVIDIA (NVDA) ...

Gorey brother and sister George and Hannah Power-Nugent were the star attraction last week as the Marie Keating Foundation ...

Informa's move means its annual meeting will in effect be online-only for UK-based share owners as they would struggle to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The guidelines include disease-specific recommendations screening, monitoring disease progression, and treatment options for ILD.

In this video, Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute, discusses results of the TRADE study, which she presented at ASCO Annual ...

Introduction The global bioconjugation market is witnessing robust growth, primarily driven by the expanding demand for targeted therapies and ...

Beyond the discount and dividend, ETO’s 12.3% annualized return on NAV (orange line above) should also be a shiny lure for ...